Notice
This is not the latest version of this item. The latest version can be found at:https://dspace.mit.edu/handle/1721.1/138782.2
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities
Author(s)
Ghattas, Majed; Dwivedi, Garima; Lavertu, Marc; Alameh, Mohamad-Gabriel
Downloadvaccines-09-01490-v2.pdf (6.233Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated, Virus-like Particles, synthetic peptide, polysaccharide, polysaccharide conjugate (glycoconjugate), viral vectored (vector-based), nucleic acids (DNA and mRNA) and bacterial vector/synthetic antigen presenting cells. Several processes are used in the manufacturing of vaccines and recent developments in medical/biomedical engineering, biology, immunology, and vaccinology have led to the emergence of innovative nucleic acid vaccines, a novel category added to conventional and subunit vaccines. In this review, we have summarized recent advances in vaccine technologies and platforms focusing on their mechanisms of action, advantages, and possible drawbacks.
Date issued
2021-12-16Publisher
Multidisciplinary Digital Publishing Institute
Citation
Vaccines 9 (12): 1490 (2021)
Version: Final published version